BioSpace News Archive

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that the company will be participating in the LD Micro Invitational XI Conference, being held virtually from June 8-10, 2021.

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthare Group, provided an update regarding the clinical development of pegunigalsidase alfa for the proposed treatment of Fabry disease.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced the appointment of Frederick Fantazzia to the position of Vice President of Sales & Marketing, North America, effective June 1, 2021.

Addition of Clinical-Scale Sachet and Blister Packaging Services Further Broadens CTS Offerings; Successful Audit of Facility by EU Qualified Person (QP) Represents Key Step for Attracting and Onboarding European CTS Customers

Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to targeted operating expenses of ~$50 million in 2022

Skylight Health has been selected as a clinical site to enroll patients for a clinical research trial investigating ADG20, a broadly neutralizing monoclonal antibody, for use in the prevention of COVID-19

Bausch Health Companies Inc. and Bausch + Lomb, its leading global eye health business, along with Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that the U.S. Food and Drug Administration has accepted the resubmitted New Drug Application for XIPERE™

Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, announced the appointment of Brad Dahms as Chief Financial Officer.

Company remains on track to announce update on enrollment, dose escalation and age de-escalation in late 2021 and interim data by year-end 2021

Virios Therapeutics, Inc. announced that clinical data from its Phase 2a trial of IMC-1 in fibromyalgia is featured in a poster presentation at the annual EULAR European Congress of Rheumatology, a renowned forum for interaction between medical doctors, scientists, people with arthritis/rheumatism, health professionals and representatives of the pharmaceutical industry worldwide, which is being held virtually June 2 - 5, 2021.